Vertex Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 32 analysts polled by S&P Global, Vertex Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $549.29. The average 1-year stock price forecast is 28.28% higher than the current stock price, while the lowest is $330 (-22.93%) and the highest is $641 (+49.70%).

Price Target: $549.29 (+28.28%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$330	$549.29	$556.5	$641
Change	-22.93%	+28.28%	+29.96%	+49.70%

Analyst Ratings

The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	7	8	8	10	10	10
Buy	9	12	12	12	12	12
Hold	8	7	7	7	7	6
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	24	27	27	29	29	28

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Eliana Merle Barclays	Barclays	Buy Maintains $607 → $615	Buy	Maintains	$607 → $615	+43.62%	May 6, 2026
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Hold Maintains $437 → $436	Hold	Maintains	$437 → $436	+1.82%	May 5, 2026
Terence Flynn Morgan Stanley	Morgan Stanley	Buy Maintains $612 → $616	Buy	Maintains	$612 → $616	+43.86%	May 5, 2026
William Pickering Bernstein	Bernstein	Buy Maintains $577 → $572	Buy	Maintains	$577 → $572	+33.58%	May 5, 2026
Brian Abrahams RBC Capital	RBC Capital	Buy Maintains $541 → $543	Buy	Maintains	$541 → $543	+26.81%	May 5, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

13.33B

from 12.00B

11.03%

from 12.00B

Revenue Next Year

14.69B

from 13.33B

10.21%

from 13.33B

EPS This Year

19.47

from 15.32

27.11%

from 15.32

EPS Next Year

22.16

from 19.47

13.81%

from 19.47

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	7.57B	8.93B	9.87B	11.02B	12.00B	13.33B	14.69B
Revenue Growth	22.06%	17.91%	10.51%	11.66%	8.90%	11.03%	10.21%
EPS	9.01	12.82	13.89	-2.08	15.32	19.47	22.16
EPS Growth	-12.44%	42.29%	8.35%	-	-	27.11%	13.81%
Forward PE	-	-	-	-	-	21.99	19.32
No. Analysts	-	-	-	-	-	35	34

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	13.9B	17.2B
Avg	13.3B	14.7B
Low	12.7B	13.1B

Revenue Growth

Revenue Growth	2026	2027
High	16.1%	29.2%
Avg	11.0%	10.2%
Low	5.8%	-1.4%

EPS Forecast

EPS	2026	2027
High	22.16	28.00
Avg	19.47	22.16
Low	16.99	16.11

EPS Growth

EPS Growth	2026	2027
High	44.6%	43.8%
Avg	27.1%	13.8%
Low	10.9%	-17.3%

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.